Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Core Insights - Sensei Biotherapeutics, Inc. is a clinical stage company focused on developing next-generation therapeutics for cancer patients [1] - The company will present at two scientific conferences in November 2024, showcasing its innovative research in cancer therapies [1] Conference and Presentation Details - Sensei Biotherapeutics will present at the PEGS Europe: Protein and Antibody Engineering Summit from November 5-7, 2024, in Barcelona, Spain [1] - The presentation titled "Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody" will be delivered by Dr. Edward van der Horst on November 5, 2024, at 9:00 a.m. CET [1] - The company will also present at the Society for Immunotherapy Cancer (SITC) 39th Annual Meeting from November 6-10, 2024, in Houston, Texas [1] - The poster presentation titled "Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications" will be presented by Dr. F. Donelson Smith on November 9, 2024, during two sessions [1] Company Overview - Sensei Biotherapeutics utilizes its TMAb™ (Tumor Microenvironment Activated biologics) platform to develop conditionally active therapeutics [1] - The lead investigational candidate, SNS-101, is designed to block the VISTA checkpoint selectively within the low pH tumor microenvironment [1] - The company is also developing additional candidates, including SNS-102, SNS-103, and SNS-201, targeting various immunosuppressive signals in the tumor microenvironment [1]